NCI Research Specialist/Clinician Scientist Award for Urologic Oncology Research

项目摘要 作为一名泌尿肿瘤科医生，我的大多数同行都尽可能地专注于手术 希望他们的努力能在个人层面上产生积极的影响。在NCI期间， 作为泌尿肿瘤学奖学金，我被临床发现的力量所吸引， 临床研究者。外科医生在该领域创造范式转变的研究路径有限 在手术室之外，因为工业界经常忽视我们面临的许多关键问题。 幸运的是，NIH合作组网络试验为临床科学家提供了一条途径， 通过与志同道合的人，病人的倡导者，翻译， 研究人员、统计人员和业务人员。通过早期参与SWOG，我已经 提供了参与和领导几项临床试验的机会，然后在 翻译研究倡议。这巩固了我作为一名临床科学家的热情， 肾癌的新举措。我很幸运能在2010年担任联合主席， SWOG肾脏小组委员会和NCI肾脏工作组。这些领导角色使我能够 为下一代的临床试验打下基础这也包括我参与了一个小肾 旨在减少过度治疗的大规模试验，通过临床试验计划开发 肾脏工作组的大部分成员召开了会议，并在今年的SWOG中被列为优先事项， 计划在今年晚些时候进行GU指导委员会的审查。尽管接受学术和领导 认可，我在NCI临床研究通过试验参与，行政 工作，SWOG调查员的指导，方案制定，以及一年两次的旅行 会议，有在加州大学洛杉矶分校为这些努力的机构支持有限。同样，NCI 申办的试验给工作人员和研究者带来了经济负担， 工业试验。我的参与很大程度上是因为我热衷于为病人提供一个 改善护理的机会。R50研究专家奖机制认可 个人可以发挥关键作用，以促进临床科学，并可以显着提高我的 工作特别是，与此奖项相关的财政支持将进一步促进我的参与， 在现有的NIH方案中，为方案开发提供时间，包括我们新的小肾 大众概念，提供前往SWOG和肾脏工作组会议的方式，并允许 SWOG和肾脏工作组领导层要求的指定保护时间。这个奖项 在我的学术生涯发展中， 临床生产的压力。我很高兴有这个机会，并感谢加州大学洛杉矶分校承认 我为这次提名所做的努力

Project Summary As a urologic oncologist, most of my peers have focused on operating as much as possible with the hope their efforts could positively effect change on an individual level. During my NCI Urologic Oncology Fellowship, I was drawn to the power of clinical discovery working alongside clinical investigators. A surgeon has limited research paths to create paradigm shifts in the field beyond the operating room, as industry often ignores many of the critical questions facing us. Fortunately, the NIH Cooperative Group network trials provide an avenue for clinical scientists to impact the field by interacting with likeminded individuals, patient advocates, translational researchers, statisticians, and operational staff. By early engagement in SWOG, I have been afforded the opportunity to participate and lead several clinical trials before taking larger roles in translational research initiatives. This cemented my passion as a clinician scientist hoping to lead new initiatives in kidney cancer. I am fortunate to have assumed Co-Chair responsibilities within SWOG’s Renal Subcommittee and the NCI Renal Task Force. These leadership roles allow me to imprint the next generation of clinical trials. This also includes my involvement with a small renal mass trial aimed at reducing overtreatment, that was developed through a Clinical Trials Planning Meeting by much of the Renal Task Force and has been prioritized within SWOG this year with plans for GU Steering Committee review later this year. Despite receiving academic and leadership recognition, my engagement in NCI clinical research throughtrial participation, administrative efforts, mentorship of SWOG investigators, protocol development, and travel for bi-annual meetings, there is limited institutional support at UCLA for these endeavors. Similarly, the NCI sponsored trials have resulted in a financial burden to staff and this investigator, as compared to industry trials. Participation has largely been a result of my passion to provide patients an opportunity for improved care. The R50 Research Specialist Award mechanism recognizes the critical role that individuals can play to advance clinical science and can significantly advance my work. In particular, the financial support associated with this Award will further my engagement in available NIH protocols, provide time for protocol development including our new Small Renal Mass Concept, provide the means to travel to SWOG and Renal Task force meetings, and allow designated protected time that SWOG and Renal Task Force leadership requires. This Award would be instrumental in my academic career development during a time where the is increasing pressure to produce clinically. I am thrilled for this opportunity and appreciate UCLA recognizing my efforts with this nomination.